Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Launched by AVIDITY BIOSCIENCES, INC. · Aug 7, 2024
Trial Information
Current as of April 30, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study will continue to evaluate the safety, tolerability, and efficacy of AOC 1020 in participants who were treated in the randomized, placebo-controlled, Phase 1/2 AOC 1020-CS1 clinical study.
Participants from AOC 1020-CS1 are eligible to enroll in AOC 1020-CS2 if they have satisfactorily completed AOC 1020-CS1. All participants who enroll in AOC 1020-CS2 will receive AOC 1020 regardless of whether they received AOC 1020 or placebo in AOC 1020-CS1. Dosing will occur every 6 to 7 weeks (twice quarterly).
The total duration of active treatment in AOC 1020-CS2 is approximately 22 mont...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Ability to provide written informed consent (signed and dated) and any authorizations required by local law and be willing and able to comply with all study requirements. When enrolling participants who are minors, it is necessary to also obtain consent from a legally designated representative and the participant will receive information in a way adapted to their age and mental maturity.
- 2. Completion of AOC 1020-CS1 with the following as judged by the Investigator and Sponsor:
- • 1. No significant tolerability issues
- • 2. Satisfactory compliance with the AOC 1020-CS1 protocol requirements
- Exclusion Criteria:
- • 1. Pregnancy, intent to become pregnant during the clinical study, or active breastfeeding.
- • 2. Unwilling or unable to continue to comply with contraceptive requirements for the length of AOC 1020-CS2.
- • 3. Any new conditions or worsening of existing condition(s) that in the opinion of the Investigator or Sponsor would make the participant unsuitable for the study or could interfere with participation or completion of the study. (Note: FSHD progression is not exclusionary, even if the participant no longer has the ability to walk 10 meters without a walker or two canes.)
About Avidity Biosciences, Inc.
Avidity Biosciences, Inc. is a pioneering biotechnology company focused on developing innovative therapeutics for the treatment of serious diseases. Leveraging its proprietary Avidity™ platform, the company specializes in advancing antibody-drug conjugates and other targeted therapies that enhance the delivery and efficacy of biologics. With a commitment to transforming patient outcomes, Avidity Biosciences aims to address unmet medical needs through cutting-edge research and development, fostering collaborations to drive forward the next generation of biopharmaceuticals.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Columbus, Ohio, United States
Durham, North Carolina, United States
Rochester, New York, United States
Seattle, Washington, United States
Palo Alto, California, United States
Gainesville, Florida, United States
Denver, Colorado, United States
Richmond, Virginia, United States
Los Angeles, California, United States
Dallas, Texas, United States
San Diego, California, United States
Ottawa, Ontario, Canada
Durham, North Carolina, United States
Sheffield, , United Kingdom
Atlanta, Georgia, United States
Kansas City, Kansas, United States
London, , United Kingdom
Patients applied
Trial Officials
Amy Halseth, Ph.D.
Study Director
Avidity Biosciences, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported